A drug screening study conducted by the National Institute of Allergy and Infectious Diseases revealed that one of PanBiokem’s synthetic compounds (hereafter JKOR) demonstrated a dose dependent broadspectrum antiviral activity against a number of enveloped viruses, e.g., a coronavirus, influenza A and B viruses, respiratory virus, rhinovirus, measles virus, and a parainfluenza virus.
A drug screening study conducted by the National Institute of Allergy and Infectious Diseases revealed that one of PanBiokem’s synthetic compounds (hereafter JKOR) demonstrated a dose dependent broadspectrum antiviral activity against a number of enveloped viruses, e.g., a coronavirus, influenza A and B viruses, respiratory virus, rhinovirus, measles virus, and a parainfluenza virus.
Separate collaborative studies at Southwest Foundation for Biomedical Research (now Texas Biomedical Research Institute, San Antonio, Texas) demonstrated that JKOR effectively inactivated HIV-1 in human T cells. However, JKOR had no antiviral effect on non-enveloped viruses. The mechanism of action is suspected to involve the cross-linking / disruption of certain glycoproteins on the viral envelope.
Preliminary in-vivo studies indicating a wide therapeutic window were encouraging. Subsequently, the safety, tolerability and efficacy of JKOR was evaluated in several human volunteers. All participants treated with JKOR for viral infections rapidly recuperated after 24 to 48 hours without any adverse symptoms or reaction, said Dr. Kirpal Gulliya, President and CEO of PanBiokem.
JKOR is inexpensive to synthesize, has a long shelf life at room temperature, and could save lives worldwide in current COVID-19 and future pandemics.